Cerulean Scientific

Executive Summary

Cerulean Scientific is a privately held medical device company based in Cambridge, MA, founded in 2007. The company addresses a critical, persistent challenge in healthcare: the high failure rates of medical devices due to clogging, obstruction, and biofouling. These failures lead to patient suffering and increased healthcare costs. Cerulean Scientific aims to redefine the standard of care by developing innovative devices engineered to resist these common failure modes. Their technology leverages advanced materials and surface engineering to maintain device functionality over extended periods, potentially reducing the need for replacements and interventions. While the company is categorized under drug delivery and small molecules, its core innovation lies in device design that prevents fouling—a problem that affects catheters, stents, and other implantable or internal devices. With a focus on reliability, Cerulean Scientific's solutions could significantly improve patient outcomes and operational efficiency in clinical settings. The company's technology platform appears robust, though specific details on revenue, funding, or regulatory filings are not publicly disclosed. As a private entity operating for nearly two decades, Cerulean Scientific has likely navigated early development phases and may be approaching commercialization. The market for anti-fouling medical devices is substantial, driven by an aging population and increasing prevalence of chronic conditions requiring long-term device use. If successful, Cerulean Scientific could capture a meaningful share of this market, particularly in high-volume applications such as dialysis catheters, central venous lines, and implantable pumps. The company's impact could extend beyond device reliability to include cost savings for healthcare systems and improved quality of life for patients. However, without additional public information, the company's current financial health and competitive positioning remain uncertain.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for novel anti-clogging catheter60% success
• Q4 2026Strategic partnership with major medical device manufacturer for distribution50% success
• Q2 2026Publication of clinical study results demonstrating reduced biofilm formation70% success